Madrigal Pharmaceuticals, Inc. $MDGL
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING2
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Resmetirom NCT05500222 |
P3 | Active, not recruiting | NASH; Cirrhosis, Liver | 845 | 2026-12 (+16 mo) |
| Resmetirom NCT04951219 |
P3 | Active, not recruiting | Non-Alcoholic Fatty Liver Disease | 810 | 2027-03 (+51 mo) |
| MAESTRO-NASH NCT03900429 |
P3 | Active, not recruiting | NASH - Nonalcoholic Steatohepatitis | 1759 | 2028-01 (+78 mo) |
| Resmetirom NCT07335601 |
P2 | Recruiting | MASH - Metabolic Dysfunction-Associated Steatohepatitis | 120 | 2028-08 |
| Resmetirom NCT07763015 |
P2 | Recruiting | MASH; MASH - Metabolic Dysfunction-Associated Steatohepatitis | 61 | 2029-07 |